Forian Inc., a leader in data science-driven information and analytics solutions for the life science, healthcare, and financial services industries, has announced its financial results for the second quarter of 2025. The company reported a significant 56% increase in revenue, reaching $7.5 million, up from $4.8 million in the same period last year. This growth is attributed to strategic contract renewals, new client acquisitions, and operational efficiencies.
The net income for the quarter stood at $0.2 million, or $0.01 per share, a substantial improvement from a net loss of $2.6 million, or $0.08 per share, in the second quarter of 2024. Adjusted EBITDA also saw a dramatic increase to $0.6 million, compared to $0.1 million in the prior year, highlighting the company's enhanced profitability and margin expansion.
Max Wygod, CEO and Executive Chairman of Forian, emphasized the company's focus on both organic growth and strategic investments to strengthen its platform and deliver value across the healthcare ecosystem. The company's cash, cash equivalents, and marketable securities totaled $35.6 million as of June 30, 2025, providing a solid foundation for future growth and investment.
Forian has also reconfirmed its full-year 2025 outlook, expecting revenue to be in the range of $28 to $30 million and Adjusted EBITDA between ($1.0) to $1.0 million. This optimistic forecast reflects the company's confidence in its business model and market position.
Investors and interested parties can access more information about Forian's financial performance and future prospects by visiting the company's website at https://www.forian.com. The company will also host a conference call and webcast to discuss these results in detail, available at https://edge.media-server.com/mmc/p/76de8mny.
Forian's performance in the second quarter of 2025 demonstrates its ability to navigate the competitive landscape of data science and analytics, delivering innovative solutions that meet the evolving needs of its clients. The company's financial health and strategic direction position it well for continued success in the dynamic healthcare and life sciences sectors.
